Connor, Clark & Lunn Investment Management (CC&L)
GALT icon

Connor, Clark & Lunn Investment Management (CC&L)’s Galectin Therapeutics GALT Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-16,611
Closed -$37.5K – 1517
2024
Q2 		$37.5K Buy
+16,611
New +$50.5K ﹤0.01% 1334
2023
Q4 		– Sell
-10,049
Closed -$19.3K – 1446
2023
Q3 		$19.3K Sell
10,049
-5,884
-37% -$9.68K ﹤0.01% 1330
2023
Q2 		$22.9K Buy
+15,933
New +$27K ﹤0.01% 1283

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s GALT Position: Q3 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Galectin Therapeutics (GALT) in Q3 2024, closing a stake of 16,611 shares — an estimated $37.5K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in GALT in Q2 2023 and held it in 3 quarters. The position peaked at $37.5K in Q2 2024. 79 funds tracked by Wall St. Rank hold GALT as of Q3 2024.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Galectin Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 16,611 Galectin Therapeutics shares in Q3 2024, an estimated $37.5K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Galectin Therapeutics in Q2 2023 and held it in 3 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Galectin Therapeutics position peaked at $37.5K in Q2 2024.
  • 79 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2024, filed 8 Nov 2024.